Abstract
Although the search for pharmacologic inhibitors of telomerase activity represents a promising approach for telomerase-based anti-cancer therapy, the immunological properties of the telomerase reverse transcriptase hTERT suggest that the enzyme is also an attractive target for novel immunotherapies against cancer. Data from both human and murine systems demonstrate that cytotoxic T-lymphocytes (CTL) can recognize peptides derived from TERT and kill TERT-positive tumor cells of multiple histologies. Given the vast overexpression of hTERT in human tumors and its low-level expression in rare normal tissues, clinical trials have begun that test the credentials of hTERT as a broadly applicable target for immunotherapy of cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Arai J, Yasukawa M, Ohminami H, Kakimoto M, Hasegawa A, Fujita S . 2001 Blood 97: 2903–2907
Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE . 1998 Science 279: 349–352
Chames P, Hufton SE, Coulie PG, Uchanska-Ziegler B, Hoogenboom HR . 2000 Proc. Natl. Acad. Sci. USA 97: 7969–7974
Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB, Bacchetti S . 1992 EMBO J. 11: 1921–1929
Counter CM, Botelho FM, Wang P, Harley CB, Bacchetti S . 1994 J. Virol. 68: 3410–3414
Counter CM, Meyerson M, Eaton EN, Ellisen LW, Caddle SD, Haber DA, Weinberg RA . 1998 Oncogene 16: 1217–1222
Gilboa E . 1999 Immunity 11: 263–270
Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA . 1999a Nature 400: 464–468
Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, Beijersbergen RL, Knoll JH, Meyerson M, Weinberg RA . 1999b Nat. Med. 5: 1164–1170
Harle-Bachor C, Boukamp P . 1996 Proc. Natl. Acad. Sci. USA 93: 6476–6481
Harley CB, Kim NW, Prowse KR, Weinrich SL, Hirsch KS, West MD, Bacchetti S, Hirte HW, Counter CM, Greider CW, Wright WE, Shay JW . 1994 Cold Spring Harb. Symp. Quant. Biol. 59: 307–315
Harrington L, Zhou W, McPhail T, Oulton R, Yeung DS, Mar V, Bass MB, Robinson MO . 1997 Genes Dev. 11: 3109–3115
Heiser A, Maurice MA, Yancey DR, Coleman DM, Dahm P, Vieweg J . 2001a Cancer Res. 61: 3388–3393
Heiser A, Maurice MA, Yancey DR, Wu NZ, Dahm P, Pruitt SK, Boczkowski D, Nair SK, Ballo MS, Gilboa E, Vieweg J . 2001b J. Immunol. 166: 2953–2960
Herbert B, Pitts AE, Baker SI, Hamilton SE, Wright WE, Shay JW, Corey DR . 1999 Proc. Natl. Acad. Sci. USA 96: 14276–14281
Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R . 1996 Nat. Med. 2: 52–58
Jager E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A . 1996 Int. J. Cancer 66: 470–476
Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW . 1994 Science 266: 2011–2015
Kolquist KA, Ellisen LW, Counter CM, Meyerson M, Tan LK, Weinberg RA, Haber DA, Gerald WL . 1998 Nat. Genet. 19: 182–186
Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM . 1999 Nat. Med. 5: 677–685
Liu K, Hodes RJ, Weng N . 2001 J. Immunol. 166: 4826–4830
Liu K, Schoonmaker MM, Levine BL, June CH, Hodes RJ, Weng NP . 1999 Proc. Natl. Acad. Sci. USA 96: 5147–5152
Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, Weinberg RA . 1997 Cell 90: 785–795
Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M . 2000 Proc. Natl. Acad. Sci. USA 97: 4796–4801
Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, Vieweg J, Gilboa E . 2000 Nat. Med. 6: 1011–1017
Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, Cech TR . 1997 Science 277: 955–959
Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D . 1998 Nat. Med. 4: 328–332
Norrback KF, Roos G . 1997 Eur. J. Cancer 33: 774–780
Pittet MJ, Valmori D, Dunbar PR, Speiser DE, Lienard D, Lejeune F, Fleischhauer K, Cerundolo V, Cerottini JC, Romero P . 1999 J. Exp. Med. 190: 705–715
Ramakrishnan S, Eppenberger U, Mueller H, Shinkai Y, Narayanan R . 1998 Cancer Res. 58: 622–625
Rosenberg SA . 1997 Immunol. Today 18: 175–182
Rosenberg SA . 2001 Nature 411: 380–384
Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE . 1998 Nat. Med. 4: 321–327
Schirle M, Keilholz W, Weber B, Gouttefangeas C, Dumrese T, Becker HD, Stevanovic S, Rammensee HG . 2000 Eur. J. Immunol. 30: 2216–2225
Schultze JL, Vonderheide RH . 2001 Trends Immunol. 22: 516–523
Shay JW, Bacchetti S . 1997 Eur. J. Cancer 33: 787–791
Simon RM, Steinberg SM, Hamilton M, Hildesheim A, Khleif S, Kwak LW, Mackall CL, Schlom J, Topalian SL, Berzofsky JA . 2001 J. Clin. Oncol. 19: 1848–1854
Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G . 1999 J. Exp. Med. 190: 1669–1678
Valmori D, Pittet MJ, Vonarbourg C, Rimoldi D, Lienard D, Speiser D, Dunbar R, Cerundolo V, Cerottini JC, Romero P . 1999 Cancer Res. 59: 4050–4055
Van den Eynde BJ, van der Bruggen P . 1997 Curr. Opin. Immunol. 9: 684–693
Van Pel A, van der Bruggen P, Coulie PG, Brichard VG, Lethe B, van den Eynde B, Uyttenhove C, Renauld JC, Boon T . 1995 Immunol. Rev. 145: 229–250
Vaziri H, Benchimol S . 1998 Curr. Biol. 8: 279–282
Vonderheide RH, Anderson KS, Hahn W, Butler MO, Schultze JL, Nadler LM . 2001 Clin. Cancer Res. 7: 3343–3348
Vonderheide RH, Hahn WC, Schultze JL, Nadler LM . 1999 Immunity 10: 673–679
Yasumoto S, Kunimura C, Kikuchi K, Tahara H, Ohji H, Yamamoto H, Ide T, Utakoji T . 1996 Oncogene 13: 433–439
Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell SR, Greenberg PD . 2000 J. Exp. Med. 192: 1637–1644
Zhang X, Mar V, Zhou W, Harrington L, Robinson MO . 1999 Genes Dev. 13: 2388–2399
Acknowledgements
I thank Drs JL Schultze, WC Hahn and LM Nadler for their valuable contributions to this project and gratefully acknowledge Drs WN Haining and SM Domchek for their critical review of the manuscript. This project is supported by the Damon Runyon Cancer Research Fund Clinical Investigator Award.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vonderheide, R. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 21, 674–679 (2002). https://doi.org/10.1038/sj.onc.1205074
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205074
Keywords
This article is cited by
-
Therapeutic Targets in Telomerase and Telomere Biology of Cancers
Indian Journal of Clinical Biochemistry (2020)
-
Effects of Influenza Derived Peptide on CD8 T Cell Responses to MHC Class I-Restricted Human Telomerase Reverse Transcriptase (hTERT)-Derived Peptide
International Journal of Peptide Research and Therapeutics (2019)
-
Cellular therapy with human autologous adipose-derived adult cells of stromal vascular fraction for alopecia areata
Stem Cell Research & Therapy (2018)
-
Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies
Genome Medicine (2016)
-
Mannan-modified adenovirus targeting TERT and VEGFR-2: A universal tumour vaccine
Scientific Reports (2015)